The question at hand is whether resistance to the antibiotic tigecycline can be reduced with a higher dosage. According to the available information, there is no definitive answer to this question.

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. It is a glycylcycline antibiotic, a class of drugs that inhibit protein synthesis in bacteria [1].

Bacterial resistance to antibiotics is a significant global health concern, and the overuse or misuse of antibiotics can contribute to the development of resistance [2]. Tigecycline has been shown to have activity against bacteria that are resistant to other antibiotics [1]. However, there is limited information available on whether increasing the dosage of tigecycline can reduce bacterial resistance.

One study examined the effect of tigecycline on bacteria that were resistant to other antibiotics [3]. The study found that tigecycline was effective against these resistant bacteria, but the dosage used in the study was not varied to determine if a higher dosage would have a different effect on bacterial resistance [3].

It is important to note that increasing the dosage of an antibiotic to treat an infection should be done with caution, as it can increase the risk of adverse effects and toxicity [2]. Additionally, increasing the dosage of an antibiotic is not a guarantee of reducing bacterial resistance [2].

In summary, based on the available information, there is no definitive answer to whether bacterial resistance to tigecycline can be reduced with a higher dosage. Further research is needed to determine the effect of tigecycline dosage on bacterial resistance.

Sources:

1. Tigecycline prescribing information. Pfizer Laboratories Div Pfizer Inc. [Online] [Cited: April 12, 2023.] <https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021857s000lbl.pdf>.
2. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention. [Online] [Cited: April 12, 2023.] <https://www.cdc.gov/drugresistance/biggest-threats.html>.
3. Zhanel GG, Harding GK, Embil JA, Siemens JL, Paterson DL. In vitro activity of tigecycline against clinical isolates of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2004;48(1):327-329. doi:10.1128/AAC.48.1.327-329.2004. [Online] [Cited: April 12, 2023.] <https://aac.asm.org/content/48/1/327>.

Additional sources:

* DrugPatentWatch.com - This source was not directly cited in the answer, but it is a reputable source for information on drug patents and pharmaceutical research and development.